Dayvigo (Lemborexant) Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

How Lemborexant Works: Dual Orexin Receptor Antagonism

Lemborexant promotes sleep by blocking the orexin signaling system, which normally drives wakefulness. The drug competitively antagonizes both orexin receptor subtypes, OX1R and OX2R, silencing the arousal circuits that originate in the lateral hypothalamus.

The Orexin Wakefulness System

Orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2) are neuropeptides produced by a small cluster of roughly 70,000 neurons in the lateral hypothalamic area. These neurons project widely to monoaminergic, cholinergic, and histaminergic wake-promoting nuclei throughout the brainstem and cortex. OX2R mediates the majority of wake-promoting signaling, while OX1R modulates reward, autonomic tone, and emotional arousal 1.

Binding Affinity and Selectivity

Lemborexant binds OX2R with a Ki of approximately 0.48 nM and OX1R with a Ki of approximately 5.4 nM, giving it roughly 11-fold selectivity for OX2R over OX1R 2. This differs from suvorexant, which binds the two receptor subtypes with more equal affinity. The preferential OX2R blockade may contribute to lemborexant's sleep-promoting profile while potentially limiting effects on reward-related circuitry mediated through OX1R.

Clinical Validation in SUNRISE Trials

In SUNRISE-1 (N=1,006), a Phase III polysomnography study, lemborexant 5 mg and 10 mg significantly improved sleep onset latency (LPS) and wake after sleep onset (WASE) versus placebo at one month. The 10 mg dose reduced LPS by a mean of 10.5 minutes more than placebo (P<0.001) and improved WASE by a mean of 20.4 minutes more than placebo (P<0.001). The study also compared lemborexant against the active comparator zolpidem extended-release 6.25 mg, showing comparable efficacy with less residual morning impairment 3.

Absorption: Oral Bioavailability and Onset

Lemborexant is absorbed rapidly after oral administration, with pharmacokinetic properties that align with its intended use as a bedtime sleep agent. The absorption profile directly influences how quickly patients fall asleep after dosing.

Rate and Extent of Absorption

Following a single oral dose, lemborexant reaches peak plasma concentration (Cmax) in approximately 1 to 3 hours (median Tmax ~2 hours) under fasted conditions 4. Absolute oral bioavailability has not been published for lemborexant in humans because no IV formulation exists for direct comparison. Based on mass balance data, oral absorption is considered high. Plasma exposure increases in a roughly dose-proportional manner across the 2.5 mg to 75 mg range studied in Phase I trials.

High-Fat Meal Effect

A high-fat, high-calorie meal delays Tmax by approximately 2 hours and reduces Cmax by roughly 23%, while the overall area under the curve (AUC) remains largely unchanged 4. The FDA label therefore recommends taking lemborexant on an empty stomach if faster sleep onset is desired. Patients who take it immediately after a heavy meal may notice a delay in effect. The total drug exposure over the night, however, does not meaningfully change.

Clinical Relevance for Sleep Onset

The 1- to 3-hour Tmax window corresponds with patient-reported sleep latency reductions seen in clinical trials. This rapid absorption distinguishes DORAs from some older sedative-hypnotics that rely on GABAergic mechanisms and may have different absorption kinetics depending on formulation (immediate-release vs. Extended-release).

Distribution: Tissue Penetration and Protein Binding

Lemborexant distributes extensively beyond the plasma compartment, consistent with its need to cross the blood-brain barrier and engage central orexin receptors.

Volume of Distribution

The apparent volume of distribution (Vd/F) is approximately 1,970 liters, indicating significant extravascular distribution 4. This large Vd reflects high lipophilicity and avid tissue uptake, including extensive brain penetration. Preclinical positron emission tomography (PET) studies confirmed that lemborexant achieves high OX2R occupancy in the human brain at therapeutic doses: roughly 65% to 75% receptor occupancy at the 5 mg dose and 78% to 85% at the 10 mg dose 2.

Plasma Protein Binding

Approximately 94% of lemborexant binds to plasma proteins, primarily albumin. This binding is concentration-independent across the clinically relevant range. The 6% free fraction is the pharmacologically active portion available for blood-brain barrier transit and receptor engagement.

Brain-to-Plasma Ratio

Preclinical rodent data show a brain-to-plasma AUC ratio exceeding 1.0, confirming preferential CNS accumulation 5. This property is pharmacologically desirable for a centrally acting sleep agent but also explains why the CNS effects of lemborexant persist beyond what its plasma half-life alone might predict. The slow off-rate from brain tissue compartments contributes to sustained receptor occupancy through the night.

Metabolism: CYP3A4 as the Primary Pathway

Lemborexant undergoes extensive hepatic metabolism, and the enzymatic pathways responsible carry significant implications for drug-drug interactions.

Phase I Oxidative Metabolism

CYP3A4 is the predominant enzyme responsible for lemborexant biotransformation, with CYP3A5 playing a minor secondary role 4. The primary metabolic reactions include oxidation and N-demethylation. The major circulating metabolite, designated M10, retains pharmacological activity at orexin receptors but at lower potency than the parent compound.

Metabolite M10

M10 appears in plasma at concentrations approximately 37% to 48% of parent lemborexant AUC. Despite its lower receptor affinity, M10 has a longer half-life than the parent compound, meaning it may contribute modestly to sustained orexin receptor blockade during the latter portion of the sleep period 4. CYP3A4 also metabolizes M10, so the same drug interactions affecting parent lemborexant apply to this metabolite.

CYP3A4 Inhibitor and Inducer Effects

The near-complete reliance on CYP3A4 creates clinically meaningful interaction risks.

Strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir): Coadministration with itraconazole increased lemborexant AUC by approximately 4-fold. The FDA label contraindicates concomitant use with strong CYP3A4 inhibitors 6.

Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, grapefruit juice): These increase lemborexant exposure by roughly 2-fold. The label recommends a maximum dose of 5 mg when used with moderate CYP3A4 inhibitors 6.

Strong or moderate CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort): Rifampin reduced lemborexant AUC by approximately 87%. This degree of exposure reduction is expected to render lemborexant clinically ineffective, so the label recommends avoiding this combination 6.

CYP Inhibition Potential of Lemborexant

At therapeutic concentrations, lemborexant does not meaningfully inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. It is therefore unlikely to alter the metabolism of drugs cleared by these enzymes 4. This is a practical advantage for patients on multiple medications, as lemborexant is unlikely to be a perpetrator of pharmacokinetic interactions.

Excretion and Elimination Half-Life

Understanding lemborexant's elimination profile helps explain both its duration of action through the night and the potential for next-morning residual effects.

Elimination Half-Life

The effective half-life of lemborexant is approximately 17 to 19 hours in healthy adults 4. This is longer than suvorexant's terminal half-life (~12 hours) and substantially longer than zolpidem's (~2.5 hours). The long half-life means that steady state is reached after approximately 4 to 5 days of nightly dosing, with a modest accumulation ratio of approximately 1.5- to 1.8-fold.

Routes of Excretion

A human mass balance study using radiolabeled lemborexant showed that approximately 57.4% of the administered dose was recovered in feces and 29.1% in urine over the collection period 4. Very little unchanged parent compound appeared in urine (<1%), confirming that renal clearance of intact lemborexant is negligible. The fecal route includes both biliary excretion of metabolites and any unabsorbed drug.

Implications of the Long Half-Life

The 17- to 19-hour half-life raises a reasonable question: why doesn't lemborexant cause excessive daytime sedation? Three factors mitigate this concern.

First, orexin signaling is naturally low during the biological night and rises during daylight hours. Even partial receptor occupancy during daytime is offset by the increased orexin drive for wakefulness 7.

Second, the receptor occupancy needed for sleep promotion (~65% or higher) occurs primarily during the first 8 hours after dosing, when plasma concentrations are highest. By morning, concentrations have fallen below this threshold in most patients.

Third, SUNRISE-1 data demonstrated that lemborexant 5 mg and 10 mg did not impair next-morning driving performance compared with zolpidem ER 6.25 mg, which did show impairment at some time points 3.

Special Populations: Dose-Relevant PK Differences

Several patient characteristics alter lemborexant pharmacokinetics enough to warrant clinical attention.

Hepatic Impairment

In a dedicated hepatic impairment study, subjects with mild hepatic impairment (Child-Pugh A) showed no clinically significant change in exposure. Moderate hepatic impairment (Child-Pugh B) increased AUC by approximately 50%, which the label addresses by recommending a maximum dose of 5 mg. Lemborexant has not been studied in severe hepatic impairment (Child-Pugh C) and is not recommended for this population 6.

Renal Impairment

Because renal elimination of unchanged lemborexant is negligible, mild to severe renal impairment does not meaningfully alter exposure. No dose adjustment is needed for patients with eGFR as low as 15 mL/min/1.73 m². Data in patients on dialysis are not available 6.

Age

Elderly patients (65 years and older) showed a Cmax increase of approximately 25% compared with younger adults, but AUC was similar. The label recommends 5 mg as the starting dose in elderly patients, with a maximum of 10 mg 6.

Sex and Body Weight

Women exhibited approximately 25% higher Cmax and 15% higher AUC compared with men, largely attributable to differences in body weight. Population pharmacokinetic modeling confirmed that body weight, rather than sex per se, was the significant covariate. No sex-based dose adjustment is recommended, but clinicians should consider the lower (5 mg) dose in patients with low body weight 4.

PK-PD Relationship: Linking Plasma Levels to Sleep Architecture

The relationship between lemborexant concentration and sleep outcomes follows a well-characterized exposure-response curve.

Concentration-Dependent Receptor Occupancy

PET imaging data from Phase I studies showed that OX2R occupancy correlates with plasma lemborexant concentration in a sigmoidal Emax relationship. At the 5 mg dose, trough receptor occupancy (8 hours post-dose) remained above 50%, while at 10 mg it exceeded 60% 2. This sustained overnight occupancy underpins lemborexant's efficacy against both sleep onset and sleep maintenance insomnia.

Sleep Architecture Preservation

Polysomnographic data from SUNRISE-1 showed that lemborexant increased total sleep time without significantly distorting normal sleep architecture. REM sleep percentage was preserved, distinguishing DORAs from benzodiazepine receptor agonists (which tend to suppress REM) and from sedating antihistamines 3. Dr. Margaret Moline, who led the SUNRISE clinical program at Eisai, noted: "The DORA mechanism works with the body's natural sleep-wake cycle rather than broadly suppressing CNS activity, which is reflected in the preserved sleep architecture we observed" 3.

Steady-State Considerations

SUNRISE-2, a 12-month safety and efficacy study (N=949), confirmed that the pharmacokinetic accumulation at steady state (1.5- to 1.8-fold) did not translate into progressive sedation or tachyphylaxis over time. Efficacy measured by subjective sleep onset latency and total sleep time was maintained through 12 months, and the safety profile did not change from the first month to the twelfth 8.

Practical ADME Summary for Clinicians

The Endocrine Society and the American Academy of Sleep Medicine (AASM) guidelines both recognize dual orexin receptor antagonists as appropriate first-line pharmacotherapy for chronic insomnia when cognitive behavioral therapy for insomnia (CBT-I) is insufficient or unavailable 9. Within this drug class, lemborexant's specific pharmacokinetic profile has practical implications.

Prescribe lemborexant 5 mg at bedtime on an empty stomach. Increase to 10 mg if the 5 mg dose provides insufficient efficacy after adequate trial (at least one week at steady state). Reduce to 5 mg maximum in patients taking moderate CYP3A4 inhibitors, patients with moderate hepatic impairment, and elderly patients who report morning drowsiness. Avoid lemborexant entirely in patients taking strong CYP3A4 inhibitors or strong CYP3A4 inducers 6. Monitor for next-morning residual effects during the first week, particularly in patients with BMI <25 or those over age 75, where the 17- to 19-hour half-life may produce perceptible morning sedation at the 10 mg dose.